Forte Biosciences (FBRX) Notes Payables (2016 - 2020)

Forte Biosciences (FBRX) has reported Notes Payables for 5 consecutive years, with $5.0 million the latest figure, recorded in Q1 2020.

• In Q1 2020, Notes Payables rose 126.0% year-over-year to $5.0 million; the TTM figure through Mar 2020 stood at $5.0 million (up 126.0% YoY), while the FY2019 annual figure was $4.7 million, changed N/A from the prior year.
• Notes Payables rose to $5.0 million in Q1 2020 per FBRX's latest filing, from $4.7 million in the prior quarter.
• Across five years, Notes Payables topped out at $27.8 million in Q3 2019 and bottomed at $2.2 million in Q1 2019.
• Historically, Notes Payables has averaged $7.9 million across 5 years, with a median of $7.2 million in 2016.
• Annual changes were most pronounced in 2019 — Notes Payables slumped 69.39% — and 2020, when it soared 126.0%.
• Forte Biosciences' Notes Payables stood at $7.2 million in 2016, then changed by 0.0% to $7.2 million in 2017, then changed by 0.0% to $7.2 million in 2018, then slumped by 34.11% to $4.7 million in 2019, then climbed by 5.0% to $5.0 million in 2020.
• Business Quant data shows FBRX's Notes Payables at $5.0 million in Q1 2020, $4.7 million in Q4 2019, and $27.8 million in Q3 2019.